Behind the Headlines: 2025 Wish List

Behind the Headlines is a bi-weekly panel discussion examining the latest trends, readouts, and other factors that drive pharmaceutical news and innovation. Each episode features consultants, venture capitalists, scientists, patient advocates, and journalists discussing the prior weeks’ top news while seeking to highlight the more enduring lessons that hide behind the headlines.

In episode 9, we’re joined by Dr. Vanessa Almendro, PhD, MBA, VP, Head of Science & Technology Innovation at Danaher Corporation; Elliot Berger, Board of Directors and Strategic Advisor at Orientation Marketing; Benjamin McLeod, founder at Convey Bio; and Turna Ray, managing editor, Precision Medicine Online, to discuss what they would most like to see happen in the bio/pharmaceutical industry in 2025.

The panel takes a look at how artificial intelligence (AI) may be used to accelerate drug discovery and development, as well as making the healthcare system more effective. Despite how AI could potentially benefit pharmaceutical processes, there is still an reluctance by some in the industry to adopt AI solutions that are already in place. AI may also be coupled with gene editing to diversify precision medicine.

Strengthening and creating new collaborative structures for rare disorders between academia and industry in 2025 may provide for the development of cost-effective personalized medicines. Gene therapies and allogeneic cell therapies will move forward, according to the panel, and messenger RNA vaccines will continue to progress in other areas besides COVID-19.

Investment, science, and technology will converge to advance these types of therapies. Biotech companies will also be investing in making glucagon-like peptide-1 (GLP-1) products more precise in the patient segmentation and expanding on applications of these types of drugs.

Click here for more episodes of Behind the Headlines.